CD28

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CD28 (CD28 Molecule) is a Protein Coding gene. Diseases associated with CD28 include Mycosis Fungoides and Sezary's Disease. Among its related pathways are Th2 Differentiation Pathway and RET signaling. Gene Ontology (GO) annotations related to this gene include identical protein binding and SH3/SH2 adaptor activity. An important paralog of this gene is CTLA4.
  • CAR Vector Products

  • AbTCR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
  • CAR Vector Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
XS-0723-LX36 Anti-cCD28 (1C6) c(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector Canine 1C6 scFv-CD28-41BB-CD4ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.